



June 17, 2016

GlycoMimetics Announces Pricing of Public Offering of Common Stock

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 3,300,000 shares of its common stock at a price to the public of \$6.10 per share. The net proceeds from the offering to GlycoMimetics are expected to be \$18.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by GlycoMimetics. The offering is expected to close on or about June 22, 2016, subject to customary closing conditions.

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated and SunTrust Robinson Humphrey, Inc. are acting as co-managers for the offering. GlycoMimetics has granted to the underwriters a 30-day option to purchase up to 495,000 additional shares of common stock at the public offering price, less the underwriting discount.

GlycoMimetics intends to use the net proceeds of the offering to conduct planned clinical trials of GMI-1271, to fund the research and development of its preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes.

A shelf registration statement relating to this offering was filed with the Securities and Exchange Commission (SEC) on March 17, 2015 and declared effective by the SEC on March 24, 2015. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com, or by phone at (877) 547-6340; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at (631) 274-2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on sickle cell disease and cancer. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML. GlycoMimetics expects to file an investigational new drug application with the U.S. Food and Drug Administration for a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist, in the third quarter of 2016. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for GlycoMimetics, Inc., including statements about the Company's anticipated public offering, anticipated use of proceeds and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in the Company's Annual Report on Form 10-K filed with the SEC on February 29, 2016 and the preliminary prospectus supplement filed with the SEC on June 16, 2016 under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the

Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20160617005346/en/): <http://www.businesswire.com/news/home/20160617005346/en/>

GlycoMimetics, Inc.

Investor Contact:

Shari Annes, 650-888-0902

sannes@annesassociates.com

or

Media Contact:

Jamie Lacey-Moreira, 410-299-3310

jamielacey@presscommpr.com

Source: GlycoMimetics, Inc.

News Provided by Acquire Media